李 枝新

Medicine & Life Sciences

1. Tuberculosis 100%
2. Cohort Studies 56%
3. Pulmonary Tuberculosis 53%
4. Chronic Obstructive Pulmonary Disease 34%
5. Single-Chain Antibodies 27%
6. Lung 23%
7. Venoms 20%
8. Nucleic Acid Amplification Techniques 19%
9. Latent Tuberculosis 19%
10. Therapeutics 19%
11. Snake Venoms 18%
12. Immunoglobulin Fragments 17%
13. Diabetes Mellitus 17%
14. Population 17%
15. Antivenins 16%
16. Time-to-Treatment 16%
17. rifapentine 15%
18. Metformin 15%
19. Naja naja 14%
20. Rifampin 14%
21. Chronic Disease Hospitals 14%
22. Acute Kidney Injury 13%
23. Interferon-gamma Release Tests 13%
24. Mycobacterium tuberculosis 13%
25. Survival 13%
26. Isoniazid 13%
27. ErbB Receptors 13%
28. Protein-Tyrosine Kinases 12%
29. Network Meta-Analysis 12%
30. Non-Small Cell Lung Carcinoma 12%
31. Dialysis 11%
32. Databases 11%
33. (1-methyl-1H-indol-5-yl)-(3,4,5-trimethoxy-phenyl)-methanone 11%
34. 2-dimethylamino-N-(1-(4-methoxybenzenesulfonyl)-2,3-dihydro-1H-indol-7-yl)acetamide 11%
35. Survivin 10%
36. Adrenal Cortex Hormones 10%
37. Angiotensin Receptor Antagonists 10%
38. National Health Programs 10%
39. Proteins 10%
40. Bacteriophages 10%
41. Adenocarcinoma of Lung 10%
42. Fluoroquinolones 10%
43. Sputum 9%
44. Chronic Kidney Failure 9%
45. Exercise 9%
46. Trimeresurus 9%
47. Angiotensin-Converting Enzyme Inhibitors 9%
48. Hydroxymethylglutaryl-CoA Reductase Inhibitors 9%
49. Artificial Respiration 9%